Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of cystic fibrosis confirmed by mutation analysis of the cystic fibrosis transmembrane conductance regulator gene~* Sputum or throat swab culture positive for Pseudomonas aeruginosa at or within 6 months of enrollment~* Age ≥12 years~* Forced expiratory volume in one second (FEV1) 25-90 percent-predicted~Exclusion Criteria:~* Age \<18 years~* Inability to routinely expectorate sputum without induction by hypertonic saline~* Inability to provide or withdrawal of written informed consent~* History of aminoglycoside sensitivity or adverse reaction to inhaled antibiotics~* Serum creatinine ≥ 2.0 mg/dl~* Serum blood urea nitrogen (BUN) ≥40 mg/dl~* Pregnancy or lactating at screening~* History of systemic intravenous anti-Pseudomonal antibiotics within 28 days of enrollment

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Continuous Therapy (Type: None): TOBI™ Podhaler™ 112 mg inhaled by mouth twice daily for 30 days followed by a 30-day cycle colistimethate 75 mg inhaled two times daily. Repeat cycle.
- Cyclic therapy (Type: None): TOBI™ Podhaler™ 112 mg inhaled by mouth twice daily for 30 days followed by a 30-day period during which no inhaled antibiotics are used. Repeat cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).